Born from exclusion and resistance, black British art has carved out creative space to tell untold stories and challenge racism, says ROGER McKENZIE
Latest editorial
Getting Orkambi on the NHS is a bittersweet victory, but the fight goes on
Your Party’s new membership rules pose a deeper question about socialist organisation: should a party lead the working class, or be led by it, says CLAUDIA WEBBE
As war engulfs Iran, many expected China to step in as a rising superpower. Instead, Beijing has chosen diplomacy over confrontation – revealing a very different vision of global leadership, argues JENNY CLEGG
The government has few aces up its sleeve when it comes to managing popular anger, argues ANDREW MURRAY
Israel's brutality in Lebanon, combined with efforts to draw the Lebanese government into negotiations, are part of a strategy to delegitimise resistance to occupation and apartheid, argues RAMZY BAROUD
KEITH FLETT looks at the state’s efforts to limit protest rights from the 19th century to today’s repression of the Palestine movement
AFTER a long and fraught four years, an agreement between Pharma company Vertex and the NHS has finally resulted in Orkambi and Symkevi, the “game-changing” cystic fibrosis drugs, being made available on the NHS.
Vertex were originally asking £100,000 per patient, per year for Orkambi, which the NHS couldn’t afford, resulting in a protracted price negotiation that above anything else illustrates a system which requires fundamental change.
This conflict between private companies and their need to give returns to their shareholders operating in the medical arena where much more is at stake was highlighted by Just Treatment patient leader Emily Birchall who said: “This is absolutely brilliant news for patients and for all the families who have fought so hard to access Orkambi and other medicines for cystic fibrosis over the last four years.
Similar stories
1943-2025: How one man’s unfinished work reveals the lethal lie of ‘colour-blind’ medicine
Politicians who continue to welcome contracts with US companies without considering the risks and consequences of total dependency in the years to come are undermining the raison d’etre of the NHS, argues Dr JOHN PUNTIS
